The Roche Group expects to raise its dividend this year on the back of a recovery in sales led by strong demand for products treating multiple sclerosis, haemophilia A, and severe eye diseases. Group sales are expected to increase by a mid-single digit figure after rising by just 1% at constant exchange rates in 2023. The expected recovery reflects sales gains by newer products which are gradually offsetting the impact of competition from biosimilar versions of the company’s leading cancer medicines.